FilingsTodayPfizer
At a glance
Pfizer reported 2025 revenue of $62.58B, down 1.6% from $63.63B in 2024. Over 4 years since 2021 ($73.64B), that is a decline of about 4% a year. Revenue peaked in 2022 at $91.79B.
In the last 12 months 4 insiders reported 3 open-market purchases ($3M) and 2 sales ($135K). None of the sales were flagged as 10b5-1 plan trades. The largest was a purchase of $1M by Chairman & CEO Albert Bourla on Aug 12, 2026. Net, insiders were buyers of $2.8M.
Pfizer filed 10 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), regulation fd disclosure (2), other events (2) and officer or director change (1). The latest officer or director change was reported on Jun 18, 2026.
2 of the 20 investors tracked here held Pfizer at the last quarter end, worth $354.2M combined. It is the largest weight for National Pension Service (Korea) (0.2% of its portfolio), followed by Bridgewater Associates (0%). New this quarter: Bridgewater Associates. Added: National Pension Service (Korea).
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $21.98B | $31.37B | $2.12B | $8.03B | $7.77B |
| Diluted EPS | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
| Dividend per share | $1.57 | $1.61 | $1.65 | $1.69 | $1.72 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined